Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7631 | PF 915275 |
| Potent and selective 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor (Ki = 2.3 nM) that displays little activity at 11βHSD2 (1.5% inhibition at 10 μM). Inhibits the conversion of prednisone to prednisolone in human hepatocytes in vitro (EC50 = 15 nM) and has antidiabetic activity in vivo. Orally active. | |
| BCC7632 | Metyrapone |
| Cytochrome P450 inhibitor. Blocks glucocorticoid synthesis via inhibition of steroid 11-β hydroxylase (CYP11B1) activity (IC50 = 7.83 μM). Also inhibits CYP3A4 and cytochrome P450-mediated ω/ω-1 hydroxylase activity. | |
| BCC7634 | AP 18 |
| Reversible TRPA1 channel blocker (IC50 values are 3.1 and 4.5 μM at human and mouse TRPA1 respectively). Blocks cinnameldehyde-induced but not capsaicin-induced nociception and reverses mechanical hyperalgesia in vivo. Also blocks TRPA1 pore dilation (IC50 = 10.3 μM for the inhibition of Yo-Pro uptake). | |
| BCC7637 | CD 3254 |
| Selective RXRα agonist; exhibits no activity at RARα, RARβ or RARγ receptors. | |
| BCC7638 | UVI 3003 |
| RXR antagonist; displays high RXR binding affinity. Does not affect the corepressor interaction capacity of the RARα subunit within the context of the RAR-RXR heterodimer. | |
| BCC7639 | SU 16f |
| Potent and selective platelet-derived growth factor receptor β (PDGFRβ) inhibitor (IC50 = 10 nM) that displays > 14-fold, > 229-fold and > 10000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively. Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 = 0.11 μM). | |
| BCC7643 | BzATP triethylammonium salt |
| Prototypic P2X7 receptor agonist that exhibits 5 - 10 fold greater potency than ATP (EC50 = 0.7 μM in HEK 293 cells; EC50 values are 3.6 and 285 μM for rat and mouse receptors respectively). Exhibits partial agonist activity at P2X1 (pEC50 = 8.7) and P2Y1 receptors and can be used as a photoaffinity label for ATPase. | |
| BCC7646 | AZ 11645373 |
| Potent and selective human P2X7 antagonist (KB values are 5 - 7 and > 10,000 nM at hP2X7 and rP2X7 respectively) that is completely without effect at all other P2X subtypes. Inhibits BzATP-mediated calcium influx and inhibits ATP-mediated IL-1β release in vitro (KB values are 15 and 92 nM respectively). | |
